Snapshot from May 31, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / People / Patrick Soon-Shiong
Person

Patrick Soon-Shiong

Tracked across 6 events · 118 articles · First seen Jan 04, 2025 · Last active May 28, 2026

Sentiment
-33
Attention
6
Events
6
Relationships
6
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (6)
4 -60
Regulatory
ImmunityBio Faces Anktiva Misleading Claims Lawsuit
ImmunityBio, a biotechnology company, is facing multiple securities class action lawsuits, initially filed by Rosen Law Firm and further investigated by Hagens Berman. The lawsuits allege that ImmunityBio and its executive chairman, Patrick Soon-Shiong, made…
Impact: Patrick Soon-Shiong, executive chairman and Chief Scientific and Medical Officer of ImmunityBio, is accused of materially overstating Anktiva's capabilities, leading to the lawsuit.
Apr 02, 2026 · 42 articles
3 -40
Business
ImmunityBio Class Action Lawsuit Filed
The Gross Law Firm has issued a notice to shareholders of ImmunityBio (NASDAQ: IBRX) regarding a class action lawsuit. The lawsuit alleges that during the period of January 19, 2026, to March 24, 2026, ImmunityBio…
Impact: Patrick Soon-Shiong is a defendant in the class action lawsuit, accused of materially overstating Anktiva's capabilities.
May 01, 2026 · 6 articles
3 -40
Business
ImmunityBio Securities Fraud Lawsuit Filed
Rosen Law Firm has filed a securities class action lawsuit against ImmunityBio, a publicly traded company, on behalf of investors who purchased its securities between January 19, 2026, and March 24, 2026. The lawsuit alleges…
Impact: Patrick Soon-Shiong is a defendant in the lawsuit, accused of materially overstating Nogapendekin alfa inbakicept's capabilities, which could harm his professional reputation.
May 01, 2026 · 6 articles
4 -60
Regulatory
ImmunityBio faces Anktiva class action
A class action lawsuit has been filed against ImmunityBio, Inc. and certain of its officers, including Defendant Soon-Shiong, by the investor-rights law firm Bronstein, Gewirtz & Grossman, LLC. The lawsuit alleges that ImmunityBio made materially…
Impact: Defendant Soon-Shiong is alleged to have materially overstated Nogapendekin alfa inbakicept's capabilities, which is a central claim in the class action lawsuit against ImmunityBio.
May 03, 2026 · 6 articles
2 0
Business
Ann Telnaes Resigns from The Washington Post
Impact: Patrick Soon-Shiong, owner of the Los Angeles Times, was included in Ann Telnaes' rejected cartoon, representing media barons seeking favor with Donald Trump.
Jan 04, 2025 · 13 articles
6 0
Regulatory
ImmunityBio Faces Securities Class Actions
Apr 01, 2026 · 45 articles
Key Actions (1)
90 Patrick Soon-Shiong made misleading claimsImmunityBio Faces Anktiva...
Relationships (6)
ImmunityBio executive chairman ↔ Patrick Soon-Shiong Patrick Soon-Shiong serves as the Executive Chairman and Chief Scientific and Me
ImmunityBio ↔ Patrick Soon-Shiong
Hagens Berman ↔ Patrick Soon-Shiong
Hagens Berman ↔ Patrick Soon-Shiong
United States — Food and Drug Administration ↔ Patrick Soon-Shiong
United States — Food and Drug Administration ↔ Patrick Soon-Shiong
NEWSDESK
Track Patrick Soon-Shiong live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.